Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 11/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138113 | 0.87 | HTR7 (0.54) | HTR7KDM4EALDH1A1GAAMAPT | |
| SCHEMBL1138131 | 0.76 | HTR7 (0.48) | HTR7TACR1DRD2DRD4DRD3 | |
| SCHEMBL1138323 | 0.76 | HTR7 (0.57) | HTR7TACR1DRD2DRD4DRD3 | |
| SCHEMBL32667521 | 0.76 | HTR7 (0.57) | HTR7TACR1DRD2DRD4DRD3 | |
| SCHEMBL1111700 | 0.76 | HTR7 (0.50) | HTR7TACR1DRD2DRD4DRD3 | |
| SCHEMBL9951391 | 0.75 | TACR1 (0.65) | HTR7TACR1HRH3 | |
| SCHEMBL1540391 | 0.75 | HTR7 (0.60) | HTR7TACR1DRD2DRD4DRD3 | |
| SCHEMBL15938091 | 0.74 | HTR7 (0.81) | HTR7TACR1DRD2DRD4DRD3 | |
| SCHEMBL28230641 | 0.73 | HTR7 (0.80) | HTR7TACR1DRD2DRD4DRD3 | |
| SCHEMBL1138483 | 0.71 | MEN1 (0.56) | DRD2DRD3KDM4EALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487810-B9 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2011-02-23 | — | — | EP | disclosed |
| EP-1487810-B1 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2010-02-17 | — | — | EP | disclosed |
| US-7297697-B2 | with alkenyl moiety substituted at the 1-position of the piperazine unit; useful in the treatment of histamine mediated diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-11-20 | — | — | US | disclosed |
| US-20050107393-A1 | 4-(diarylmethyl)-1-piperazinyl derivatives | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-05-19 | — | — | US | disclosed |
| EP-1487810-A2 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | Sun Pharmaceuticals Industries Ltd. (IN) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003079970-A2 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107393-A1 | 4-(diarylmethyl)-1-piperazinyl derivatives | NPY2R, NPY1R, CBR3 | HTR7 776/4885TACR1 194/4885DRD2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.